🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Syngene International Limited SYNGENE NIFTY_SMALLNSEPHARMA

Healthcare · Diagnostics & Research · India
https://www.syngeneintl.com

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

READ MORE ›
₹442.00
-31.63% 1Y

Market & Price

Market Cap
₹17,761.82 Cr
Current Price
₹442.00
High / Low (52W)
₹722.05 / ₹389.90
Beta
0.03

Valuation

Stock P/E
56.16
Industry PE
37.60
Forward P/E
34.55
PEG Ratio
-
Book Value
₹117.84
Price to Book
3.75
P/S
4.75
EV/EBITDA
17.29
Dividend Yield
0.28%

Profitability & Returns

ROCE
8.35%
ROE
6.62%
ROA
4.75%
Profit Margin
8.47%
Op Margin
20.55%
EPS (Latest Qtr)
₹3.67
EPS (TTM)
₹7.87

Balance Sheet & Liquidity

Debt/Equity
0.09
Quick Ratio
1.18
Current Ratio
1.38
Debt
₹458.40 Cr
Total Assets
₹7,054.70 Cr
Current Assets
₹2,142.80 Cr
Working Capital
₹590.50 Cr

Ownership

Promoter Holding
52.99%
Chg in Prom Hold
-
FII / Inst Holding
38.46%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹16,933.38 Cr
Total Revenue (TTM)
₹3,738.70 Cr
EBITDA
₹979.40 Cr
Free Cash Flow
₹725.76 Cr
Operating Cash Flow
₹915.20 Cr
Shares Outstanding
₹40.18 Cr
Gross Margin
75.43%
Payout Ratio
15.88%

Growth (CAGR)

Revenue 5Y
6.67%
Profit 5Y
-11.98%
Revenue (YoY)
1.80%
Earnings (YoY)
-19.50%

PROS

  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 56.2.
  • Earnings shrank at -12.0% CAGR over 5 years.
  • Trading 38.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SYNGENE Syngene International Limited NIFTY_SMALLNSEPHARMA 442.00 56.16 ₹17,761.82 Cr 0.28% 8.35% 6.62% 6.67% -11.98%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
Ad space

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue 943.70 Cr1,018.00 Cr874.50 Cr917.10 Cr1,036.50 Cr
Cost of Revenue 237.40 Cr235.00 Cr217.60 Cr229.40 Cr233.10 Cr
Gross Profit 706.30 Cr783.00 Cr656.90 Cr687.70 Cr803.40 Cr
Operating Expenses 533.10 Cr540.90 Cr556.90 Cr569.00 Cr590.40 Cr
Operating Income 173.20 Cr242.10 Cr100.00 Cr118.70 Cr213.00 Cr
EBITDA 301.90 Cr362.50 Cr224.10 Cr154.00 Cr319.60 Cr
Interest Expense 12.40 Cr15.90 Cr11.60 Cr11.90 Cr12.10 Cr
Pretax Income 180.80 Cr240.50 Cr101.30 Cr28.40 Cr196.00 Cr
Tax Provision 49.70 Cr57.20 Cr14.60 Cr13.40 Cr48.10 Cr
Net Income 131.10 Cr183.30 Cr86.70 Cr15.00 Cr147.90 Cr
Diluted EPS 3.264.562.150.373.67

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -3,080.20 Cr3,369.50 Cr3,642.40 Cr3,738.70 Cr
Cost of Revenue -860.20 Cr930.20 Cr942.50 Cr918.60 Cr
Gross Profit -2,220.00 Cr2,439.30 Cr2,699.90 Cr2,820.10 Cr
Operating Expenses -1,601.80 Cr1,792.20 Cr2,088.80 Cr2,293.60 Cr
Operating Income -618.20 Cr647.10 Cr611.10 Cr526.50 Cr
EBITDA -994.60 Cr1,091.80 Cr1,145.60 Cr912.60 Cr
Interest Expense -34.50 Cr45.10 Cr53.10 Cr48.80 Cr
Pretax Income -593.60 Cr620.80 Cr659.90 Cr410.90 Cr
Tax Provision -129.20 Cr110.80 Cr163.70 Cr94.20 Cr
Net Income -464.40 Cr510.00 Cr496.20 Cr316.70 Cr
Diluted EPS 9.8211.5112.6912.34-

Compounded Sales Growth

5 Years:6.67%
1 Year:1.80%

Compounded Profit Growth

5 Years:-11.98%
1 Year:-19.50%

Stock Price Performance

1 Year:-31.63%
6 Months:-30.91%
3 Months:-1.11%
1 Month:+2.28%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -5,831.00 Cr6,151.60 Cr6,795.90 Cr7,054.70 Cr
Current Assets -2,425.30 Cr1,959.00 Cr2,287.30 Cr2,142.80 Cr
Cash & Equivalents -87.00 Cr85.60 Cr366.90 Cr228.60 Cr
Inventory -332.80 Cr238.50 Cr155.50 Cr141.30 Cr
Receivables -529.30 Cr441.60 Cr526.80 Cr508.80 Cr
Total Liabilities -2,213.00 Cr1,893.90 Cr2,069.10 Cr2,215.60 Cr
Current Liabilities -1,188.20 Cr1,144.30 Cr1,396.40 Cr1,552.30 Cr
Long Term Debt 531.50 Cr489.00 Cr100.00 Cr0-
Total Debt -815.20 Cr555.20 Cr577.90 Cr458.40 Cr
Total Equity -3,618.00 Cr4,257.70 Cr4,726.80 Cr4,839.10 Cr
Shares Outstanding -40.14 Cr40.20 Cr40.25 Cr40.29 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -823.50 Cr1,042.10 Cr1,167.60 Cr915.20 Cr
Investing Cash Flow --656.40 Cr-495.60 Cr-744.70 Cr-860.40 Cr
Financing Cash Flow --342.50 Cr-551.40 Cr-141.80 Cr-215.00 Cr
Capital Expenditure --518.30 Cr-510.80 Cr-770.10 Cr-368.20 Cr
Free Cash Flow -305.20 Cr531.30 Cr397.50 Cr547.00 Cr
Net Change in Cash --175.40 Cr-4.90 Cr281.10 Cr-160.20 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -72.1%72.4%74.1%75.4%
Operating Margin % -20.1%19.2%16.8%14.1%
Net Margin % -15.1%15.1%13.6%8.5%
ROE % -12.8%12.0%10.5%6.5%
ROCE % -13.3%12.9%11.3%9.6%

Shareholding Pattern

Insiders
52.99%
Institutions
38.46%
Public Float
81.81%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SYNGENE

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks